Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Merck & Co. (NYSE: MRK) | Delayed: 145.27 -1.97 (1.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.24 | 52 Week High | $65.46 | |||
| Open | $145.02 | 52 Week Low | $47.97 | |||
| Day High | $145.44 | P/E | 98.82 | |||
| Day Low | $143.41 | EPS | $1.47 | |||
| Volume | 8,381,045 | |||||
